https://www.onclive.com/conference-coverage/asco-2020/encorafenibbinimetinib-combo-continues-to-show-survival-benefits-in-braf-v600mutant-melanoma
May 30th, 2020 - The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600–mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/hero-trial-suggests-relugolix-to-become-new-standard-for-tsuppression-in-advanced-prostate-cancer
May 30th, 2020 - Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer, according to findings from the phase 3 HERO trial, presented at the 2020 ASCO Virtual Scientific Meeting.
https://www.onclive.com/conference-coverage/asco-2020/frontline-pembrolizumabaxitinib-survival-benefit-upholds-in-advanced-rcc
May 30th, 2020 - The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) continued to demonstrate a clinically significant improvement in progression-free and overall survival (OS) compared with sunitinib (Sutent) in patients with previously untreated, advanced renal cell carcinoma (RCC), according to updated findings of the phase 3 KEYNOTE-426 trial that were presented during the 2020 ASCO Virtual Sc...
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl
May 30th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
https://www.onclive.com/conference-coverage/asco-2020/frontline-durvalumab-maintains-os-benefit-in-updated-essclc-findings
May 30th, 2020 - The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl
May 30th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/mirvetuximab-soravtansine-combination-shows-positive-response-tolerability-in-ovarian-cancer
May 30th, 2020 - Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates (ORRs) regardless of platinum status with a favorable tolerability profile, according to a study presented at the 2020 ASCO Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/tislelizumab-frontline-combos-extend-pfs-in-squamous-nsclc
May 30th, 2020 - Combining the anti–PD-1 agent tislelizumab (BGB-A317) with chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer (NSCLC), according to findings from the phase 3 BGB-A317-307 trial presenting during the 2020 ASCO Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/update-sustains-os-benefit-with-encorafenibcetuximab-regimens-in-braf-mcrc
May 30th, 2020 - The latest results from the phase 3 BEACON CRC study continued to show an overall survival (OS) benefit for encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer (mCRC).
https://www.targetedonc.com/view/encorafenib-cetuximab-combos-sustain-os-benefit-in-braf-metastatic-colorectal-cancer
May 30th, 2020 - Encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) continued to show an overall survival benefit compared with cetuximab plus irinotecan-based regimens as treatment of patients with BRAF-mutated metastatic colorectal cancer (mCRC) in the updated findings from the phase 3 BEACON CRC clinical trial.
https://www.targetedonc.com/view/her2-colorectal-and-gastric-gej-cancers-demonstrate-responses-to-fam-trastuzumab-deruxtecan
May 30th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Both studies had results presented at the 2020 ASCO Virtual Scientific Program.
https://www.targetedonc.com/view/teclistamab-appears-safe-efficacious-in-relapsed-refractory-multiple-myeloma
May 30th, 2020 - Teclistamab (JNJ-64007957) may be a safe and efficacious treatment option for patients with relapsed/refractory multiple myeloma, according to findings from a phase I study presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
https://www.targetedonc.com/view/pyl-pet-tracer-may-be-superior-to-standard-imaging-for-prostate-cancer
May 30th, 2020 - PSMA-targeted 18F-DCFPyL-PET/CT imaging demonstrated excellent diagnostic performance in men with biochemically relapsed prostate cancer in terms of a correct localization rate that far exceeded the criteria to meet the primary end point, according to findings from the phase 3 CONDOR trial.
https://ascopost.com/videos/asco20-virtual-scientific-program/david-fajgenbaum-on-chasing-his-cure-for-castleman-disease/
May 30th, 2020 - David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.
https://ascopost.com/videos/asco20-virtual-scientific-program/jeffrey-meyerhardt-on-celecoxib-and-folfox-for-stage-iii-colon-cancer/
May 30th, 2020 - Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival (Abstract 4003).
https://ascopost.com/videos/asco20-virtual-scientific-program/merry-jennifer-markham-perspectives-on-three-abstracts/
May 30th, 2020 - Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.
https://ascopost.com/videos/asco20-virtual-scientific-program/roy-herbst-on-osimertinib-in-stage-ib-iiia-egfr-mutation-positive-nsclc/
May 30th, 2020 - Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).
https://ascopost.com/videos/asco20-virtual-scientific-program/scott-kopetz-on-encorafenib-plus-cetuximab-with-or-without-binimetinib-in-colorectal-cancer/
May 30th, 2020 - Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate in previously treated patients with BRAF V600E–mutated metastatic colorectal cancer (Abstract 4001).
https://ascopost.com/videos/asco20-virtual-scientific-program/shaji-kumar-on-carfilzomib-lenalidomide-bortezomib-and-dexamethasone-in-multiple-myeloma/
May 30th, 2020 - Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200198/full/
May 30th, 2020 - A nurse-led telephone triage (NTT) system in Italy helped patients with cancer manage their symptoms at home and reduced hospitalizations and costs of care, according to a new study presented during the ASCO20 Virtual Scientific Program (Abstract 2002).
